The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Optimizing the diagnostic process for MDS: advances in genetics and digital tools
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, comments on the evolution of diagnosing myelodysplastic syndromes (MDS) and the potential for optimizing the process. Prof. Mittelman notes that while traditional bone marrow examination is still used, advances in genetics and digital tools may enable more accurate and objective diagnoses, potentially allowing for blood tests to replace bone marrow biopsies in certain cases. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This is a very interesting question, the diagnosis of MDS, because had we talked just a few years ago, the idea was that we are still based on bone marrow, which is the old traditional way. However, in these days, we are in a kind of transition. We are still based on bone marrow examination, looking at the morphology, counting blasts, as well as genetics and flow cytometry, which can help. However, there are several reports today that suggest that probably we may be able to diagnose MDS more accurately and more objectively...
This is a very interesting question, the diagnosis of MDS, because had we talked just a few years ago, the idea was that we are still based on bone marrow, which is the old traditional way. However, in these days, we are in a kind of transition. We are still based on bone marrow examination, looking at the morphology, counting blasts, as well as genetics and flow cytometry, which can help. However, there are several reports today that suggest that probably we may be able to diagnose MDS more accurately and more objectively. And this is based on genetics, and this is based on additional tools, such as digital tools. And hopefully this may be able to be done by testing blood, peripheral blood only, without bone marrow. So still, if you are talking about the end of 2024 or 2025, which is coming, yes, we still do bone marrow to all patients that have to be diagnosed. But probably in the next few years, we will talk about additional new methodology which might be able to skip bone marrow examination, at least in a certain percentage of our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
FibroGen: Other: Speaker; Abbvie: Research Funding; BMS: Research Funding; Novartis: Research Funding; Johnson & Johnson: Research Funding; CannaLean: Other: Shares; Dr. Reddy: Consultancy; BioConvergence: Consultancy; Roche: Research Funding.
